To functionally test if mutations resulting from MMR deficiency can activate enhancers, we set out to introduce signature MMR mutations in CRC cells in a manner that recapitulates the natural way in which these mutations arise in MSI tumors. The gene discussed is MRC1; the disease is colorectal carcinoma.